Angiopoietin-2: An attractive target for improved antiangiogenic tumor therapy

Cancer Research

Volumn 73, Issue 6, 2013, Pages 1649-1657

  Gerald, Damien ^a   Chintharlapalli, Sudhakar ^a   Augustin, Hellmut G ^b,c   Benjamin, Laura E ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTB 1003; AMG 780; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; ARRY 614; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CEDIRANIB; CEP 11981; CVX 060; DOCETAXEL; ERLOTINIB; FORETINIB; IRINOTECAN; MEDI 3617; MGCD 265; MONOCLONAL ANTIBODY DC101; NESVACUMAB; PACLITAXEL; PF 04856884; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; SORAFENIB; TIE 1 RECEPTOR; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER REGRESSION; CANCER THERAPY; COLON CANCER; COLORECTAL CANCER; DEGRADATION; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; DYSGEUSIA; ENDOTHELIUM CELL; FATIGUE; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; INTERNALIZATION; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; METASTASIS INHIBITION; METASTASIS POTENTIAL; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-2; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84875456598     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4697     Document Type: Review

References (66)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011;10:417-27.
3. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009;10:165-77.
4. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994;8:1897-909.
5. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-80.
6. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
7. Goede V, Schmidt T, Kimmina S, Kozian D, Augustin HG. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 1998;78:1385-94.
8. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997;277:48-50.
9. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
10. Rao S, Lobov IB, Vallance JE, Tsujikawa K, Shiojima I, Akunuru S, et al. Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch. Development 2007;134:4449-58.
11. Thomas M, Felcht M, Kruse K, Kretschmer S, Deppermann C, Biesdorf A, et al. Angiopoietin-2 stimulation of endothelial cells induces alphavbeta3 integrin internalization and degradation. J Biol Chem 2010; 285:23842-9.
12. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endotheliumthrough an internal autocrine loop mechanism. J Cell Sci 2005;118:771-80.
13. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006;12:235-9.
14. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004;103:4150-6.
15. Reiss Y, Droste J, Heil M, Tribulova S, Schmidt MH, Schaper W, et al. Angiopoietin-2 impairs revascularization after limb ischemia. Circ Res 2007;101:88-96.
16. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998;153:1459-66.
17. Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 2009;29:2011-22.
18. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002;3:411-23.
19. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011;19:512-26.
20. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007;109: 5276-85.
21. Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C, et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 2010;70:5270-80.
22. Puri MC, Rossant J, Alitalo K, Bernstein A, Partanen J. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J 1995;14:5884-91.
23. Porat RM, Grunewald M, Globerman A, Itin A, Barshtein G, Alhonen L, et al. Specific induction of tie1 promoter by disturbed flow in atherosclerosis- prone vascular niches and flow-obstructing pathologies. Circ Res 2004;94:394-401.
24. Hansen TM, Singh H, Tahir TA, Brindle NP. Effects of angiopoietins-1 and -2 on the receptor tyrosine kinase Tie2 are differentially regulated at the endothelial cell surface. Cell Signal 2010;22:527-32.
25. Saharinen P, Kerkela K, Ekman N, Marron M, Brindle N, Lee GM, et al. Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2. J Cell Biol 2005;169:239-43.
26. Seegar TC, Eller B, Tzvetkova-Robev D, Kolev MV, Henderson SC, Nikolov DB, et al. Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands. Mol Cell 2010;37:643-55.
27. Felcht M, Luck R, Schering A, Seidel P, Srivastava K, Hu J, et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest 2012;122:1991-2005.
28. Coxon A, Bready J, Min H, Kaufman S, Leal J, Yu D, et al. Contextdependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin- 1/2-neutralizing peptibody. Mol Cancer Ther 2010;9:2641-51.
29. Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 2013;73:108-18.
30. Davis S, Papadopoulos N, Aldrich TH, Maisonpierre PC, Huang T, Kovac L, et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol 2003;10:38-44.
31. Jeansson M, Gawlik A, Anderson G, Li C, Kerjaschki D, Henkelman M, et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest 2011;121:2278-89.
32. Strumberg D, Schultheis B. Regorafenib for cancer. Expert Opin Invest Drugs 2012;21:879-89.
33. McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS. Feature Article: Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc Natl Acad Sci U S A 2012; 109:18281-9.
34. Besterman JM, Fournel M, Dupont I, Bonfils C, Dubay M, Ste-Croix CR, et al. Potent preclinical antitumor activity of MGCD265, an oral Met/ VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib. J Clin Oncol 28, 2010 (suppl; abstr e13595).
35. Huang H, Lai JY, Do J, Liu D, Li L, Del Rosario J, et al. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 2011;17: 1001-11.
36. Rini BI, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, et al. AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study. J Clin Oncol 29: 2011 (suppl 7; abstr 309).
37. Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012;30:362-71.
38. Gaast AV, van Hagen P, Hulshof M, Richel D, van Berge Henegouwen MI, Nieuwenhuijzen GA, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. J Clin Oncol 28: 400s, 2010 (suppl; abstr 5042).
39. Available from: www.clinicaltrial.gov. [Cited 2012 Dec.]
40. Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, et al. Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A 2010; 107:22611-6.
41. Rosen LS, Mendelson DS, Cohen RB, Gordon MS, Goldman JW, Bear IK, et al. First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. J Clin Oncol 28: 210s, 2010 (suppl 15; abstr 2524).
42. Natale RB, Rizvi NA, Infante JR, Joseph LJ, Viner J, McDevitt JT, et al. Safety, pharmacokinetics, and antitumor activity of MEDI3617, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 30: 2012 (suppl; abstr TPS2621).
43. Hashizume H, Falcon BL, Kuroda T, Baluk P, Coxon A, Yu D, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010;70:2213-23.
44. Imanishi Y, Hu B, Jarzynka MJ, Guo P, Elishaev E, Bar-Joseph I, et al. Angiopoietin-2 stimulates breast cancer metastasis through the alpha (5)beta(1) integrin-mediated pathway. Cancer Res 2007;67:4254-63.
45. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15:102-11.
46. Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo- controlled, phase 3 trial. Lancet 2013;381:303-12.
47. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245-55.
48. Schmieder R, Ellinghaus P, Scholz A, Bhargava A, WilhelmSM, Zopf D, et al. Regorafenib (BAY 73-4506): anti-metastatic activity in a mouse model of colorectal cancer [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; 2012. Abstract nr 2337.
49. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012;2:270-87.
50. MethylGene initiates phase II program for MGCD265 in solid tumors and non-small cell lung cancer patients. MethylGene Inc Press Release, 2009:September 02.
51. Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs 2012;30: 1352-60.
52. Patel K, Fattaey A, Burd A. ACTB-1003: An oral kinase inhibitor targeting cancer mutations (FGFR), angiogenesis (VEGFR2, TEK), and induction of apoptosis (RSK and p70S6K) J Clin Oncol 28, 2010 (suppl; abstr e13665).
53. Hudkins RL, Becknell NC, Zulli AL, Underiner TL, Angeles TS, Aimone LD, et al. Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12, 13-dihydro-2-methyl-8-(pyrimidin- 2-ylamino)-4H-indazolo[5, 4-a]pyrrolo[3,4-c] carbazol-4-one (CEP- 11981): a novel oncology therapeutic agent. J Med Chem 2012;55: 903-13.
54. Komrokji RS, List AF, Khoury HJ, Lancet JE, Jabbour E, Foudray MC, et al. Phase 1 dose-escalation/expansion study of the p38/Tie2 inhibitor ARRY-614 in patients with IPSS Low/Int-1 risk myelodysplastic syndromes [abstract]. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13 San Diego, CA. Abstract nr 118.
55. Gross S, Winski S, Pheneger J, Anderson D, Munson M, Rodriguez M, et al. ARRY-614, a small molecule inhibitor of p38, Abl, Tie2 and VEGFR2 with multiple potential therapeutic applications [abstract]. In: Kinases Proceedings of the Cancer Meeting: Lessons from the Clinic 2006; 2006 Feb 14-19; Santa Fe, New Mexico, Abstract nr 14.
56. Dieras V, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, et al. A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC). J Clin Oncol 29: 2011 (suppl; abstr 544).
57. Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin- 2. Cancer Cell 2004;6:507-16.
58. MEDI-3617 ANGIO 2012: antiangiogenic therapy. In: Proceedings of the 14th International Symposium; 2012 Feb 2-4; La Jolla, CA.
59. Leow CC, Coffman K, Inigo I, Breen S, Czapiga M, Soukharev S, et al. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncol 2012;40:1321-30.
60. Papadopoulos KP, Chau NG, Patnaik A, Adriaens L, Lalani AS, Daly C, et al. A phase I first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies. J Clin Oncol 29: 2011 (suppl; abstr TPS159).
61. Lalani AS, Castanaro C, Kyle AH, Minchinton AI, Thurston G, Daly C. Combined blockade of VEGF and Ang2 promotes dramatic tumor necrosis and growth inhibition of colorectal cancer xenografts [abstract]. In: Proceedings of the Molecular Targets and Cancer Therapeutics Meeting; 2011 Nov 12-16; San Francisco, CA. Abstract: nr A10.
62. Daly C, Castanaro C, Adler AP, Eichten A, Lalani AS, Papadopoulos NJ, et al. REGN910, a fully-human, Ang2-specific monoclonal antibody, inhibits tumor growth as a monotherapy and dramatically potentiates the effects of VEGF Trap (Aflibercept) [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Chicago, IL. Philadelphia (PA): AACR; 2011. Abstract nr 3290.
63. Thomas M, Kienast Y, Scheuer W, Lorenzon E, Herting F, Odin M, et al. Dual inhibition of Ang-2 andVEGF via a novel human bispecific bivalent IgG1 CrossMAb shows potent antiangiogenic, antitumoral, and antimetastatic efficacy and leads to a reduced side effect profile compared to single therapies [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; 2012. Abstract nr 2319.
64. Rennel ES, Regula JT, Harper SJ, Thomas M, Klein C, Bates DO, et al.A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis. Microcirculation, 2011;18:598-607.
65. Roschke V, Lafleur D, Hilbert D, Kiener P, inventors; Zyngenia, Inc., assignee. ANG-2 binding complexes and uses thereof. United States patent WO-2012009705. 2012 Jan 19.
66. Palmer GM, Tiran Z, Zhou Z, Capozzi ME, Park W, Coletta C, et al. A novel angiopoietin-derived peptide displays antiangiogenic activity and inhibits tumour-induced and retinal neovascularization. Br J Pharmacol 2012;165:1891-903.